Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
58 studies found for:    Alisertib AND cancer
Show Display Options
Rank Status Study
1 Active, not recruiting Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Conditions: Hepatoblastoma;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Kidney Neoplasm;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma
Interventions: Drug: Alisertib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
2 Recruiting Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
Conditions: Breast Cancer;   Breast Carcinoma;   Breast Tumors;   Malignant Neoplasm of Breast
Interventions: Drug: Paclitaxel;   Drug: Alisertib
3 Active, not recruiting Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IIIA Colon Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: irinotecan hydrochloride;   Drug: alisertib
4 Not yet recruiting Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
Conditions: Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs
Interventions: Drug: Alisertib;   Drug: TAK-228
5 Recruiting Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: alisertib;   Drug: gemcitabine
6 Active, not recruiting MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Conditions: Ovarian Carcinoma;   Fallopian Tube Cancer;   Peritoneal Cancer;   Breast Carcinoma
Interventions: Drug: MLN8237 + Paclitaxel;   Drug: MLN8237+Paclitaxel vs. Paclitaxel alone
7 Not yet recruiting Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   Postmenopausal;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Alisertib;   Drug: Fulvestrant;   Other: Laboratory Biomarker Analysis
8 Active, not recruiting Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Conditions: Estrogen Receptor Positive;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Alisertib;   Drug: Fulvestrant;   Other: Laboratory Biomarker Analysis
9 Active, not recruiting Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: Alisertib;   Drug: Abiraterone acetate;   Drug: Prednisone
10 Active, not recruiting A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Conditions: Small Cell Prostate Cancer;   Neuroendocrine Prostate Cancer;   Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers
Intervention: Drug: MLN8237
11 Recruiting Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
Conditions: Metastatic Breast Cancer;   Solid Tumors
Interventions: Drug: Alisertib;   Drug: MLN0128
12 Recruiting Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer Metastatic;   Non-small Cell Lung Cancer Recurrent
Intervention: Drug: MLN8237 and Erlotinib
13 Recruiting Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors
Condition: Malignant Digestive System Neoplasm
Interventions: Drug: Alisertib;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin
14 Active, not recruiting MLN8237 and Pazopanib in Combination for Solid Tumors
Conditions: Malignant Neoplasm of Breast;   CNS Malignancy;   Malignant Neoplasm of Gastrointestinal Tract;   Genitourinary Neoplasms Malignancy and Gender Unspecified;   Head and Neck Neoplasms;   Melanoma;   Malignant Neoplasm of Thorax
Interventions: Drug: Alisertib;   Drug: Pazopanib
15 Recruiting Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors
Conditions: Malignant Rhabdoid Tumor;   Atypical Teratoid Rhabdoid Tumor
Interventions: Drug: alisertib;   Drug: methotrexate;   Drug: cisplatin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: topotecan;   Drug: vincristine;   Procedure: Surgical resection;   Radiation: Radiation therapy
16 Not yet recruiting Alisertib in Chemotherapy-pretreated Urothelial Cancer
Conditions: Bladder Cancer;   Transitional Cell Carcinoma
Interventions: Drug: Alisertib;   Drug: Paclitaxel;   Drug: Placebo
17 Completed A Study of Alisertib (MLN8237) in Adult East Asian Patients With Advanced Solid Tumors or Lymphomas
Conditions: Advanced Solid Tumors;   Lymphomas
Intervention: Drug: Alisertib
18 Completed MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors
Conditions: Unspecified Childhood Solid Tumor, Excluding CNS;   Neuroblastoma
Intervention: Drug: MLN8237
19 Completed
Has Results
Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
Conditions: Advanced Nonhematological Malignancies;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Metastatic Breast Cancer;   Head and Neck Squamous Cell Carcinoma;   Gastroesophageal Adenocarcinoma
Intervention: Drug: MLN8237 (Alisertib)
20 Recruiting Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Conditions: Lung Cancer;   Mesothelioma
Intervention: Drug: Alisertib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years